PAG1

Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 · Q9NWQ8 · PAG1 on Sugi Atlas →

0 patent compounds predicted against PAG1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to PAG1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis PHASE1/PHASE2RECRUITING
Vaccine Treatment for Surgically Resected Pancreatic Cancer PHASE1/PHASE2COMPLETED
CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma PHASE1/PHASE2NOT_YET_RECRUITING
Acetylcarnitine and Insulin Sensitivity PHASE2COMPLETED
NG2 and DLL3 CAR-T Cells Targeting Melanoma PHASE1/PHASE2RECRUITING
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
Pembrolizumab (MK-3475) in MM Patients With Residual Disease PHASE2COMPLETED
The Effects of GLA on Human Volunteers PHASE1COMPLETED
Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Evaluation of Blood and Cardiac Protein O-GlcNAcylation Levels in Cardiac Surgery in Children nanRECRUITING
Evaluation of Blood Protein O-GlcNAcylation Levels in Children nanRECRUITING
Expression of CD19 Complex in Lymphoproliferative Disorders nanUNKNOWN
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2) nanWITHDRAWN
Immune Cell Response to Stimuli nanRECRUITING
The Molecular Biology of Paroxysmal Nocturnal Hemoglobinuria (PNH) nanCOMPLETED
A Real-world, Multi-center, Prospective, Observational Study for PNH in China nanCOMPLETED
Evaluation of a Novel PET Radioligand to Image OGA nanCOMPLETED
Duality of Lipids: the Athlete's Paradox nanCOMPLETED
Glycosylation in Patients With Galactosaemia nanCOMPLETED
Vulvodynia: Identification of Potential Relevant Biomarkers nanCOMPLETED
Biomarkers in Samples From Patients With Endometrial Cancer nanWITHDRAWN
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies nanENROLLING_BY_INVITATION
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Study of the Pathophysiological Mechanisms Involved in Bleeding Events nanCOMPLETED
Expression of Altered Glycosyltransferases, Mucins, and RTKs in Human Ovarian and Endometrial Cancers nanUNKNOWN
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation nanUNKNOWN
Genetic Susceptibility in MAlignant Pleural Mesothelioma: Clinical Implication of GermliNE variaTionS nanRECRUITING
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML) nanWITHDRAWN

Related proteins — ESM-2 sequence neighbours (a PAG1 binder may also engage these)

ProteinNameSimilarity
Q3U1F9 1.000 Q3U1F9 →
Q9JM80 0.996 Q9JM80 →
Q8N4X5 0.983 Q8N4X5 →
Q6PIZ9 0.983 Q6PIZ9 →
Q9D8L0 0.982 Q9D8L0 →
O75128 0.981 O75128 →
Q3UU67 0.980 Q3UU67 →
D3ZUI5 0.980 D3ZUI5 →
Q3UMF0 0.980 Q3UMF0 →
Q6UWF3 0.980 Q6UWF3 →
Q8C4Q9 0.980 Q8C4Q9 →
Q5JQS6 0.979 Q5JQS6 →
Q17R10 0.979 Q17R10 →
Q6ZNL6 0.979 Q6ZNL6 →
Q5NBX1 0.979 Q5NBX1 →
Q8BSM5 0.978 Q8BSM5 →
Q99ME3 0.978 Q99ME3 →
Q3SYX1 0.978 Q3SYX1 →
Q9NWN3 0.978 Q9NWN3 →
Q5S7W5 0.978 Q5S7W5 →
O54957 0.978 O54957 →
O43561 0.977 O43561 →
O46600 0.977 O46600 →
Q9NW97 0.977 Q9NW97 →
Q8K3I4 0.977 Q8K3I4 →
A4IGN8 0.977 A4IGN8 →
O75410 0.976 O75410 →
Q9TU69 0.976 Q9TU69 →
Q3UU41 0.976 Q3UU41 →
Q8N6F7 0.976 Q8N6F7 →